Market Overview

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths globally, making early detection through screening crucial in reducing mortality rates. In North America, the demand for colorectal cancer screening tests has surged due to increased awareness, advances in diagnostic technologies, and a growing aging population. Early detection allows for timely intervention, which can significantly improve survival rates. The market for colorectal cancer screening tests in North America is poised for growth, driven by technological advancements, a higher prevalence of colorectal cancer, and greater public health initiatives.

Market Size and Share

In 2024, the North American colorectal cancer screening tests market was valued at USD 5.94 billion, reflecting the growing focus on early detection. The market is projected to grow at a compound annual growth rate (CAGR) of 5.6% during the forecast period from 2025 to 2034, reaching an estimated value of USD 9.78 billion by 2034. This growth is driven by the increasing adoption of advanced screening methods, the expanding pool of patients eligible for screening, and governmental and healthcare initiatives aimed at improving early detection and prevention.

Market Trends

• Growing Awareness of Early Detection
  Awareness about colorectal cancer and the importance of early detection is increasing across North America. Governments, healthcare organizations, and NGOs are investing in public health campaigns to encourage regular screenings for individuals above the age of 45, which has resulted in a rise in demand for colorectal cancer screening tests. As people become more conscious of the benefits of early detection, the market for screening tests continues to expand, benefiting the industry overall.
• Technological Advancements in Screening Tests
  Recent innovations in colorectal cancer screening tests, including stool-based tests and virtual colonoscopy, have contributed to the market's growth. Advancements in non-invasive techniques, such as fecal immunochemical tests (FIT) and liquid biopsy, offer more convenient and accurate alternatives to traditional colonoscopies. These technological improvements make screenings more accessible and less invasive, driving greater adoption, especially among patients reluctant to undergo traditional colonoscopies.
• Increased Prevalence of Colorectal Cancer
  The prevalence of colorectal cancer is rising in North America, partly due to an aging population and lifestyle factors such as poor diet, sedentary habits, and increased alcohol consumption. This uptick in cases has prompted greater demand for colorectal cancer screening tests. As the healthcare system shifts its focus to preventive care, colorectal cancer screening has become a key tool in reducing cancer incidence and improving long-term health outcomes for the population.
• Governmental and Insurance Support for Screenings
  Governments and insurance companies in North America are increasingly covering colorectal cancer screenings, which is contributing to market growth. For instance, the U.S. Centers for Medicare and Medicaid Services (CMS) provides coverage for CRC screening, making it more accessible to older adults. Furthermore, the implementation of national guidelines recommending screenings at an earlier age (such as the recent recommendation to start at age 45) has expanded the target population for screening, positively impacting the market.

Get a free sample request: https://www.expertmarketresearch.com/reports/north-america-colorectal-cancer-screening-tests-market/requestsample

Market Analysis

• Screening Tests Segment
  The North American colorectal cancer screening market can be categorized based on the type of tests, such as stool-based tests, colonoscopy, CT colonography (virtual colonoscopy), flexible sigmoidoscopy, and others. Among these, colonoscopy remains the gold standard for CRC screening due to its ability to detect and remove polyps. However, non-invasive options like stool-based tests and CT colonography are gaining traction due to their convenience and less invasive nature.
• End User Segment
  The primary end users of colorectal cancer screening tests in North America include hospitals, diagnostic centers, laboratories, and others. Hospitals hold a significant market share due to their access to advanced diagnostic equipment and a higher volume of patients seeking screenings. Diagnostic centers and laboratories also contribute to the market's growth by providing specialized testing services and access to advanced screening technologies for early detection.
• Technological Innovations and Adoption
  As technology continues to evolve, the market for colorectal cancer screening tests is witnessing increased adoption of digital tools, artificial intelligence (AI), and machine learning. These technologies help improve the accuracy of screenings, provide more personalized approaches to detecting colorectal cancer, and enhance the efficiency of diagnostic procedures. The incorporation of AI in image analysis for colonoscopy and virtual colonoscopy is expected to drive market growth during the forecast period.
• Regional Insights
  In North America, the United States leads the colorectal cancer screening tests market, driven by its larger healthcare infrastructure, higher awareness levels, and government-backed initiatives. The U.S. market benefits from advanced healthcare policies, widespread access to healthcare services, and a well-established screening framework. Canada also plays an important role in the market, with a robust healthcare system and governmental support for CRC screening initiatives.

Scope of the Report

This report provides a detailed analysis of the North American colorectal cancer screening tests market, examining historical trends, market dynamics, and forecasted growth from 2025 to 2034. It explores key segments within the market, including screening tests, end users, and regions, while highlighting emerging trends, opportunities, and challenges. Additionally, the report offers a comprehensive analysis of major players, market drivers, constraints, and future market prospects.

Market Growth

Several factors are fueling the growth of the colorectal cancer screening tests market. The increasing prevalence of colorectal cancer, supported by an aging population, has led to heightened demand for screening tests. Furthermore, technological advancements in screening methods are making early detection more accessible and accurate. As more individuals undergo screenings and early detection programs become more widespread, the market is poised for sustained growth. With greater adoption of advanced and non-invasive screening technologies, the future of the market looks promising.

Recent Developments & Challenges

• Technological Advancements in Screening
  The adoption of non-invasive screening tests like stool-based tests, liquid biopsy, and virtual colonoscopy is increasing. These advancements allow patients to undergo testing at home or with less discomfort, encouraging greater participation in screening programs.
• Insurance Coverage and Government Initiatives
  Governments and insurance companies are improving coverage for colorectal cancer screening tests. In the U.S., the recent lowering of the screening age to 45 under the U.S. Preventive Services Task Force (USPSTF) guidelines has increased the eligible population for screenings, further driving market demand.
• Challenges in Early Detection
  Despite the advances in screening technologies, challenges such as the need for better diagnostic tools, resistance to screening from some segments of the population, and healthcare costs remain. The industry faces hurdles in ensuring access to screenings across diverse socioeconomic groups.
• Public Awareness Campaigns
  Public health campaigns that raise awareness about the importance of colorectal cancer screening are crucial to overcoming reluctance toward testing. National organizations and healthcare providers are increasingly working together to educate people about the benefits of early detection.

Key Players

Abbott Laboratories
Abbott Laboratories is a leading player in the colorectal cancer screening market, providing innovative diagnostic solutions like the Alere™ i RSV test. Abbott focuses on developing non-invasive, quick, and accurate tests for colorectal cancer detection, offering products that cater to a wide range of healthcare providers.

Epigenomics AG
Epigenomics AG specializes in molecular diagnostics for colorectal cancer, particularly in the area of blood-based screening tests. Their cutting-edge products, such as the Epi proColon® test, offer an innovative solution for early detection of colorectal cancer, particularly for those who are reluctant to undergo invasive procedures like colonoscopy.

Exact Sciences Corporation
Exact Sciences is a pioneer in non-invasive colorectal cancer screening tests. The company's Cologuard® test is a widely recognized stool-based DNA test that allows for early detection of colorectal cancer and pre-cancerous lesions. The company is focused on expanding access to its screening technologies across North America.

Roche Diagnostics Corporation
Roche Diagnostics is a global leader in healthcare diagnostics, offering a wide range of products, including those for colorectal cancer screening. Their systems, which integrate cutting-edge diagnostic technologies, are instrumental in the early detection of colorectal cancer and enhancing patient outcomes.

Other Companies
Other notable players in the market include Siemens AG, Sysmex Inostics, Inc., EKF Diagnostics Holdings Plc, Laboratory Corporation of America® Holdings, and LetsGetChecked Inc. These companies are continually working toward developing new and improved methods for colorectal cancer screening.

FAQs

• What is the expected growth rate of the North American colorectal cancer screening tests market?
  The market is expected to grow at a CAGR of 5.6% from 2025 to 2034.
• Which screening tests are commonly used for colorectal cancer detection?
  Common tests include stool-based tests, colonoscopy, CT colonography, flexible sigmoidoscopy, and others.
• How is the government supporting colorectal cancer screening?
  Governments are increasingly providing coverage for screenings through insurance programs and public health initiatives to increase participation.
• What is driving the market for colorectal cancer screening tests in North America?
  Key drivers include technological advancements, increased prevalence of colorectal cancer, government and insurance support, and growing awareness about early detection.

More Related Report: 

Top 6 Companies in the United States Dialysis Services Market: https://www.expertmarketresearch.com/healthcare-articles/top-united-states-dialysis-services-companies
Trump’s New Tariff Plans Impact the Global Biopharma and Healthcare Industry: https://www.expertmarketresearch.com/healthcare-articles/new-tariff-plans-by-trump
Top 7 Companies in the Global Portable Medical and Healthcare Devices Market: https://www.expertmarketresearch.com/healthcare-articles/top-portable-medical-and-healthcare-devices-companies
Top 7 Pediatric Medical Device Companies & Manufacturers Worldwide: https://www.expertmarketresearch.com/healthcare-articles/top-pediatric-medical-device-companies-worldwide